Multifaceted Roles of Interleukin-6 in Adipocyte–Breast Cancer Cell Interaction
暂无分享,去创建一个
Junjeong Choi | J. Koo | Jones Gyamfi | Minseob Eom | Ja-Seung Koo | Junjeong Choi | Jones Gyamfi | M. Eom
[1] Yitao Wang,et al. Adiponectin and breast cancer , 2011, Medical oncology.
[2] S. Ivy,et al. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition , 2011, Breast Cancer Research.
[3] A. Tzankov,et al. Role of the Tumor Microenvironment in Breast Cancer , 2015, Pathobiology.
[4] S. Kihara,et al. Association of serum adiponectin levels with breast cancer risk. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] E. Palmer,et al. Identification and importance of brown adipose tissue in adult humans. , 2009, The New England journal of medicine.
[6] S. Iwase,et al. Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. , 2004, European cytokine network.
[7] B. Mroczko,et al. [Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease]. , 2007, Polskie Archiwum Medycyny Wewnetrznej.
[8] C. Giordano,et al. The Multifaceted Mechanism of Leptin Signaling within Tumor Microenvironment in Driving Breast Cancer Growth and Progression , 2014, Front. Oncol..
[9] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[10] J. Coward,et al. Interleukin-6: an angiogenic target in solid tumours. , 2014, Critical reviews in oncology/hematology.
[11] Mark A. LaBarge. On stem cells in the human breast. , 2012, Cold Spring Harbor perspectives in biology.
[12] D. Weaver,et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. , 2001, Cancer research.
[13] W. Jung,et al. Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells , 2015, Breast Cancer Research and Treatment.
[14] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[15] Mihail I Mitov,et al. Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer , 2017, Cell Death & Disease.
[16] R. DiMarchi,et al. Leptin: structure, function and biology. , 2005, Vitamins and hormones.
[17] Xin-hua Liang,et al. Links between cancer stem cells and epithelial–mesenchymal transition , 2015, OncoTargets and therapy.
[18] Peter Vaupel,et al. The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.
[19] L. Hebbard,et al. Role of Adiponectin and Its Receptors in Cancer , 2012, Cancer biology & medicine.
[20] R. Alten,et al. Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases , 2013, Annals of medicine.
[21] J. Rossi,et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer , 2010, British Journal of Cancer.
[22] B. Miroux,et al. The biology of mitochondrial uncoupling proteins. , 2004, Diabetes.
[23] J. Li,et al. CNTO-328 (Centocor). , 2005, Current opinion in investigational drugs.
[24] Hsin C. Lin,et al. Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade. , 2016, Cancer research.
[25] G. Strassmann,et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. , 1992, The Journal of clinical investigation.
[26] Jinxiang Tan,et al. Adipocyte is a non-trivial, dynamic partner of breast cancer cells. , 2011, The International journal of developmental biology.
[27] P. Lewandowski,et al. Cancer cachexia: impact, mechanisms and emerging treatments , 2012, Journal of cachexia, sarcopenia and muscle.
[28] J. Morales-Montor,et al. The role of cytokines in breast cancer development and progression. , 2015, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[29] W. Han,et al. Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism , 2016, bioRxiv.
[30] J. Kurebayashi. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications , 2000, Breast cancer.
[31] R. Carón,et al. Human breast adipose tissue: characterization of factors that change during tumor progression in human breast cancer , 2017, Journal of Experimental & Clinical Cancer Research.
[32] F. Church,et al. Mature breast adipocytes promote breast cancer cell motility. , 2012, Experimental and molecular pathology.
[33] S. Ivy,et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.
[34] M. Trikha,et al. CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice , 2004, International journal of cancer.
[35] B. Cannon,et al. The browning of white adipose tissue: some burning issues. , 2014, Cell metabolism.
[36] M. Karin,et al. Autocrine IL-6 signaling: a key event in tumorigenesis? , 2008, Cancer cell.
[37] D. McMillan,et al. Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer. , 2016, Translational research : the journal of laboratory and clinical medicine.
[38] M. Dieudonné,et al. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. , 2008, Oncology reports.
[39] A. Krešo,et al. Cancer Stem Cells and Self-renewal , 2010, Clinical Cancer Research.
[40] M. Naylor,et al. Breast cancer stem cells , 2013, Front. Physiol..
[41] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[42] C. Dray,et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. , 2013, Cancer research.
[43] Kunwei Shen,et al. Stromal cells in tumor microenvironment and breast cancer , 2012, Cancer and Metastasis Reviews.
[44] C. Buechler,et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. , 2009, Endocrine-related cancer.
[45] J. Bono,et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. , 2012, European journal of cancer.
[46] P. Seale,et al. Brown and beige fat: development, function and therapeutic potential , 2013, Nature Medicine.
[47] Haishi Qiao,et al. Human Adipocytes Stimulate Invasion of Breast Cancer MCF-7 Cells by Secreting IGFBP-2 , 2015, PloS one.
[48] C. Ghigna,et al. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression , 2017, Molecular Cancer.
[49] Genevieve Housman,et al. EMT and tumor metastasis , 2015, Clinical and Translational Medicine.
[50] E. Matera,et al. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity , 2015, Breast Cancer Research.
[51] L. Ellis,et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.
[52] P. Hojman,et al. The role of intratumoral and systemic IL-6 in breast cancer , 2013, Breast Cancer Research and Treatment.
[53] Naveena Singh,et al. Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.
[54] A. Bhatt,et al. Role of interleukin-6 in cancer progression and therapeutic resistance , 2016, Tumor Biology.
[55] Shuwei Wang,et al. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). , 2014, International journal of oncology.
[56] M. D. De Latour,et al. Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. , 2005, Biochemical and biophysical research communications.
[57] W. Scherbaum,et al. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. , 2001, The Journal of clinical endocrinology and metabolism.
[58] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[59] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[60] F. Caldefie‐Chézet,et al. Molecular mechanisms of leptin and adiponectin in breast cancer. , 2011, European journal of cancer.
[61] F. Bertucci,et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.
[62] Chia-Hung Chou,et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway , 2003, Oncogene.
[63] M. Jeschke,et al. White Adipose Tissue Browning: A Double-edged Sword , 2016, Trends in Endocrinology & Metabolism.
[64] B. Yu,et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell , 2005, Archives of pharmacal research.
[65] D. Glass,et al. Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.
[66] C. Muller. Tumour-surrounding adipocytes are active players in breast cancer progression. , 2013, Annales d'endocrinologie.
[67] M. Prentki,et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. , 2017, JCI insight.
[68] K. Baltgalvis,et al. Interleukin 6 as a Key Regulator of Muscle Mass during Cachexia , 2010, Exercise and sport sciences reviews.
[69] G. Steinberg,et al. Adipose tissue as an endocrine organ , 2010, Molecular and Cellular Endocrinology.
[70] A. Gansmuller,et al. Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. , 2005, Cancer research.
[71] L. Coussens,et al. The tumor microenvironment: a critical determinant of neoplastic evolution. , 2003, European journal of cell biology.
[72] R. Hovey,et al. Diverse and Active Roles for Adipocytes During Mammary Gland Growth and Function , 2010, Journal of Mammary Gland Biology and Neoplasia.
[73] T. Price,et al. Presence of leptin in breast cell lines and breast tumors. , 1999, Biochemical and biophysical research communications.
[74] D. Heber,et al. Preadipocytes stimulate breast cancer cell growth. , 1998, Nutrition and cancer.
[75] Miao-Fen Chen,et al. The role of IL-6 in the radiation response of prostate cancer , 2013, Radiation oncology.
[76] S. Ambs,et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression , 2014, Proceedings of the National Academy of Sciences.
[77] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[78] D. Santini,et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.
[79] J. Bromberg,et al. The IL-6 feed-forward loop: a driver of tumorigenesis. , 2014, Seminars in immunology.
[80] R. Hollingsworth,et al. Interleukin-6 Stimulates Defective Angiogenesis. , 2015, Cancer research.
[81] J. Scheller,et al. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.
[82] R. Datar,et al. Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. , 2016, Cancer research.
[83] J. Rossi,et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[84] D. Saunders,et al. Adipocyte-Tumor Cell Metabolic Crosstalk in Breast Cancer. , 2017, Trends in molecular medicine.
[85] Y. Kwon,et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. , 2013, Cellular signalling.
[86] D. Rose,et al. Angiogenesis, adipokines and breast cancer. , 2009, Cytokine & growth factor reviews.
[87] Heike Knüpfer,et al. Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.
[88] Y. DeClerck,et al. Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.
[89] Samy Lamouille,et al. Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.
[90] T. Kishimoto,et al. Interleukin-6 : discovery of a pleiotropic cytokine , 2022 .
[91] M. Vasson,et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. , 2008, Oncology reports.
[92] Qun Zhou,et al. Adipocyte activation of cancer stem cell signaling in breast cancer. , 2015, World journal of biological chemistry.
[93] Ming Li,et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.
[94] C. Heldin,et al. Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression , 2007, Cancer science.
[95] A. Xu,et al. Adiponectin Inhibits Cell Proliferation by Interacting with Several Growth Factors in an Oligomerization-dependent Manner* , 2005, Journal of Biological Chemistry.
[96] A. Axel,et al. Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer , 2007 .
[97] S. Kajimura,et al. A new era in brown adipose tissue biology: molecular control of brown fat development and energy homeostasis. , 2014, Annual review of physiology.
[98] Toshio Tanaka,et al. Therapeutic uses of anti-interleukin-6 receptor antibody. , 2015, International immunology.
[99] Sendurai A Mani,et al. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression , 2011, Breast Cancer Research.
[100] M. Takeichi,et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. , 1993, Cancer research.
[101] Bernard Klein,et al. Interleukin-6 as a Therapeutic Target , 2015, Clinical Cancer Research.
[102] Hugh M. Davis,et al. Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma , 2010, Clinical Cancer Research.
[103] Ding Cheng Yang,et al. Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells. , 2011, Anticancer research.
[104] C. D. Salcido,et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics , 2008, Breast Cancer Research.
[105] F. Sotgia,et al. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. , 2014, Seminars in oncology.
[106] M. Núñez,et al. Tumor microenvironment and breast cancer progression , 2012, Cancer biology & therapy.
[107] P. Valet,et al. Cancer-associated adipocytes promotes breast tumor radioresistance. , 2011, Biochemical and biophysical research communications.
[108] P. Porporato. Understanding cachexia as a cancer metabolism syndrome , 2016, Oncogenesis.
[109] K. Polyak,et al. The microenvironment in breast cancer progression: biology and implications for treatment , 2011, Breast Cancer Research.
[110] G. Semenza,et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.
[111] A. Puisieux,et al. Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.
[112] Y. Liu,et al. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures , 2011, International journal of oncology.
[113] Dennis C. Sgroi,et al. Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.
[114] P. Heinrich,et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.
[115] Ruo-Pan Huang,et al. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. , 2016, Biochimica et biophysica acta.
[116] Debra L. Fulton,et al. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers , 2015, Breast Cancer Research.
[117] Rong Li,et al. Interleukin 6 Secreted from Adipose Stromal Cells Promotes Migration and Invasion of Breast Cancer Cells , 2009, Oncogene.
[118] A. Aboussekhra. Role of cancer-associated fibroblasts in breast cancer development and prognosis. , 2011, The International journal of developmental biology.
[119] E. Lengyel,et al. Adipose tissue and adipocytes support tumorigenesis and metastasis. , 2013, Biochimica et biophysica acta.
[120] M. Tisdale. Biology of cachexia. , 1997, Journal of the National Cancer Institute.
[121] N. Yanaihara,et al. Antitumor effects of interleukin‐6 (IL‐6)/interleukin‐6 receptor (IL‐6R) signaling pathway inhibition in clear cell carcinoma of the ovary , 2016, Molecular carcinogenesis.
[122] Yuan Yuan Wang,et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. , 2011, Cancer research.
[123] A. Axel,et al. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[124] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[125] E. Wagner,et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. , 2014, Cell metabolism.
[126] K. Pantel,et al. The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study , 2011, The Prostate.
[127] J. Blay,et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients , 2003, British Journal of Cancer.
[128] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[129] P. Heinrich,et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.
[130] Z. Duan,et al. Interleukin-6 signaling pathway in targeted therapy for cancer. , 2012, Cancer treatment reviews.
[131] Yang Yao,et al. Interleukin-6 as a Prognostic Marker for Breast Cancer: A Meta-analysis , 2015, Tumori.
[132] K. Jamil,et al. Adiponectin and Leptin Molecular Actions and Clinical Significance in Breast Cancer , 2014, International journal of hematology-oncology and stem cell research.
[133] Kinyui A. Lo,et al. Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes , 2013, Bioscience reports.
[134] D. Santini,et al. Interleukin-6 and pro inflammatory status in the breast tumor microenvironment , 2015, World Journal of Surgical Oncology.
[135] J. Rich,et al. Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. , 2013, Endocrine-related cancer.
[136] M. Mandal,et al. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. , 2016, Cancer letters.
[137] Philippe Valet,et al. Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. , 2012, Cancer letters.
[138] A. van Oudenaarden,et al. Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity , 2016, Cell reports.